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ffects of Rosiglitazone Treatment
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OBJECTIVES We evaluated ubiquitin-proteasome activity in carotid plaques of asymptomatic and symp-
tomatic patients and the effect of rosiglitazone, a peroxisome proliferator-activated receptor-
gamma activator, in symptomatic plaques.
BACKGROUND The role of the ubiquitin-proteasome system, the major pathway for non-lysosomal
intracellular protein degradation in eucaryotic cells, in the progression of atherosclerotic
plaque to instability is unclear.
METHODS Plaques were obtained from 40 symptomatic and 38 asymptomatic patients undergoing
carotid endarterectomy. Symptomatic patients received 8 mg rosiglitazone (n  20) or
placebo (n  20) for 4 months before scheduled endarterectomy. Plaques were analyzed for
macrophages (CD68), T-lymphocytes (CD3), inflammatory cells (HLA-DR), ubiquitin-
proteasome activity, nuclear factor kappa B (NFkB), inhibitory kappa B (IkB)-beta,
nitrotyrosine, matrix metalloproteinase (MMP)-9, and collagen content (immunohistochem-
istry and enzyme-linked immunosorbent assay).
RESULTS Compared with asymptomatic plaques, symptomatic plaques had more macrophages,
T-lymphocytes, and HLA-DR cells (p  0.001); more ubiquitin-proteasome activity and
NFkB (p  0.001); and more markers of oxidative stress (nitrotyrosine and O2
 production)
and MMP-9 (p 0.01) along with a lesser collagen content and IkB-beta levels (p 0.001).
Compared with placebo-treated plaques, rosiglitazone-treated symptomatic plaques pre-
sented fewer inflammatory cells (p  0.01); less ubiquitin, proteasome 20S, and NFkB
(p  0.01); less nitrotyrosine and O2
 production (p  0.01); and greater collagen content
(p  0.01), indicating a more stable plaque phenotype.
CONCLUSIONS Ubiquitin-proteasome overactivity is associated with enhanced inflammatory reaction in
symptomatic plaques. The inhibition of ubiquitin-proteasome activity in lesions of symp-
tomatic patients by rosiglitazone is associated with plaque stabilization, possibly by down-
regulating NFkB-mediated inflammatory pathways. (J Am Coll Cardiol 2006;47:2444–55)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.01.073© 2006 by the American College of Cardiology Foundation
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fatients with substantial carotid artery narrowing are at
ncreased risk for major stroke (1), but the pathogenic
echanisms linking carotid atherosclerosis and ischemic
rain injury still need to be fully clarified. Clinical trials
esigned to evaluate the beneficial effects of endarterectomy
n symptomatic and asymptomatic patients have focused on
laque ulceration as a risk factor for cerebrovascular events (2).
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006, accepted January 29, 2006.he conversion of a stable, asymptomatic lesion to an
nstable, ruptured plaque involves many processes, such as
he inflammation that plays a central role in the cascade of
vents that eventually results in plaque erosion and fissuring
3). In fact, studies examining markers of inflammation
emonstrate a relation between inflammation and risk of
ardiovascular disease (4). Furthermore, several studies have
hown that inflammation is more common in symptomatic
laques, with greater numbers of macrophages and T-cells
etected in the cap of symptomatic plaques (5), and plaque
upture has been shown to be related to increased inflam-
ation within the plaque rather than plaque morphology or
egree of vessel stenosis (6). Thus, the identification of
athways that may regulate inflammation is critical to the
ormulation of strategies that may stabilize plaques. How-
ver, molecular mechanisms that induce inflammation and
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June 20, 2006:2444–55 Ubiquitin-Proteasome Activity in Symptomatic Plaqueubsequent plaque instability are still unknown. There is
xperimental evidence that the ubiquitin-proteasome sys-
em, the major pathway for non-lysosomal intracellular
rotein degradation in eucaryotic cells, may be involved in a
umber of biological processes, including inflammation,
roliferation, and apoptosis, that are responsible for pro-
ression of atherosclerotic plaque to an unstable phenotype
7). The ubiquitin-mediated proteolytic pathway involves the
onjugation of multiple moieties of ubiquitin, a 76-aminoacid
olypeptide, to cellular proteins in a multienzymatic process,
argeting these proteins to degradation (8). This ligation of
biquitin by a series of ubiquitin-conjugating enzymes
roduces polyubiquitin chains, which serve as targeting
ignals for degradation of the protein by the proteasome.
he multicatalytic proteasome consists of a central catalytic
ore, the 20S proteasome, and two regulatory 19S com-
lexes (9). Moreover, the ubiquitin-proteasome pathway is
equired for activation of nuclear factor kappa B (NFkB), a
entral transcription factor that regulates inflammatory
enes, by degradation of its inhibitory kappa B (IkB)
roteins (10). Although it has been demonstrated that
biquitin immunoreactivity is enhanced in autopsy coronary
pecimens from infarcted patients (11), no evidence exists
bout the potential role of the ubiquitin-proteasome system
n the evolution of atherosclerotic plaques toward instability.
e hypothesized that the ubiquitin-proteasome overactivity
ay enhance the inflammatory potential of atherosclerotic
laques favoring instability. This study was designed to
dentify differences in inflammatory infiltration and
biquitin-proteasome activity between carotid plaques of
symptomatic and symptomatic patients. Because experi-
ental and pathological studies suggest that activation of
eroxisome proliferator-activated receptor (PPAR)-gamma
ay reduce inflammation (12) and oxidative stress (13) and
nhibit ubiquitin-proteasome activity (14), the study also
valuated the effect of the PPAR-gamma agonist rosiglitazone
n ubiquitin-proteasome activity in carotid plaques of symp-
omatic patients.
ETHODS
atients. We studied 78 surgical inpatients (44 men, 34
omen) undergoing carotid endarterectomy for extracranial
Abbreviations and Acronyms
ELISA  enzyme-linked immunosorbent assay
IkB  inhibitory kappa B
MMP  matrix metalloproteinase
NFkB  nuclear factor kappa B
NO  nitric oxide
PPAR  peroxisome proliferator-activated receptor
TIA  transient ischemic attack
VSMC  vascular smooth muscle celligh-grade internal carotid artery stenosis (70% luminal carrowing). The study group comprised 38 patients with
symptomatic carotid stenosis (asymptomatic group) and 40
atients who presented with symptoms of cerebral ischemic
ttack (symptomatic group, “symptomatic” according to
orth American Symptomatic Carotid Endarterectomy
rial [NASCET] classification). Endarterectomy was per-
ormed 120 to 140 days after the onset of symptoms in these
atients. During the baseline interview, a previous stroke
as assessed by asking, “Did you ever suffer from a stroke
iagnosed by a physician?” Medical records of patients who
nswered yes were checked to verify the diagnosis. A history
f transient ischemic attack (TIA) also was assessed during
he baseline interview. All TIAs were reviewed by a neu-
ologist. A neurologist reviewed information on all possible
trokes. A stroke was diagnosed if the clinical symptoms and
euroimaging were positive. Asymptomatic patients under-
ent a baseline clinical examination as well as medical
istory and had never developed neurologic symptoms or
erebral lesions assessed by computed tomography. All
atients, both symptomatic and asymptomatic, received
omputed tomography or magnetic resonance imaging.
ercentages of carotid diameter reduction, procedural
ethods, concomitant therapy, and risk factors did not
iffer between the two groups (Table 1). By the time of
urgery, all patients were taking long-term aspirin therapy
100 mg/day). The symptomatic patients were randomized
o receive rosiglitazone (4 mg twice daily, n  20) or
lacebo (n  20) for 4 months according to human studies
valuating the carotid arterial intima-media thickness pro-
ression as well as circulating markers of inflammation after
PAR-gamma agonist treatments (12,15). After the treat-
ent period, all patients had undergone endarterectomy.
asting plasma glucose, insulin, and serum lipids, as well as
nsulin resistance index (16), were measured at baseline,
onthly, and before endarterectomy. Written informed
onsent was obtained from all patients before each examina-
ion. The local ethics review committee approved the study.
therectomy specimens. After surgery, the specimens
ere cut perpendicular to the long axis into two halves. The
rst half was frozen in liquid nitrogen for the following
nzyme-linked immunosorbent assay (ELISA) analysis. A
ortion of the other half-specimen was immediately
mmersion-fixed in 10% buffered formalin. Sections were
erially cut at 5 m, mounted on lysine-coated slides, and
tained with hematoxylin and eosin and with the trichrome
ethod. Carotid artery specimens were analyzed by light
icroscopy.
mmunohistochemistry. After the surgical procedure, sam-
les were immediately frozen in isopentane and cooled in
iquid nitrogen. Similar regions of the plaque were analyzed
Fig. 1). Serial sections were incubated with specific antibodies
nti-ubiquitin, anti-proteasome 20S, anti-alpha smooth mus-
le actin (Sigma-Aldrich Corp., Milan, Italy), anti–HLA-DR,
nti CD68 (Monoclonal Mouse Anti-Human CD68, clone
G-M1, Dako, Glostrup, Denmark), and anti-CD3 (Mono-
lonal Mouse Anti-Human CD3, clone PC3/188A, Dako);
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Ubiquitin-Proteasome Activity in Symptomatic Plaque June 20, 2006:2444–55nti–IkB-beta; and anti-matrix metalloproteinase (MMP)-9
Santa Cruz Biotechnology, Santa Cruz, California). Specific
ntibodies that selectively recognized the activated form of
uclear factor-kB (p65 and p50 subunits, Santa Cruz)
ere used. For each immunohistochemical experiment, a
egative control was performed with the primary anti-
ody omitted (data not shown). The specimens were
nalyzed by an expert pathologist (intraobserver variabil-
ty 6%) blinded to the patient’s diagnosis.
uantitative analysis for histology. CD3-positive T-cells
ere counted individually and expressed as the number of
ells per square millimeter of section area as determined by
omputer-aided planimetry (defined in later text). Further-
ore, we determined the area occupied by CD68-positive–
ich areas. Analysis of experiments was performed with a
ersonal-computer-based 24-bit color image-analysis sys-
em. In brief, electronic images were digitized with a Leica
olor video camera (Leica Microsystem, Milano, Italy). A
olor threshold mask for immunostaining was defined to
etect the red color by sampling, and the same threshold
Table 1. Characteristics of Study Patients
Variables
Asympto
Patien
Control G
(n  3
Age (years) 71 
Patient characteristics
TIA —
Stroke —
Family history of IHD 16 (42
Family history of diabetes 7 (18
Hypertension 18 (47
Hypercholesterolemia 13 (34
Diabetes 9 (24
Cigarette smoking 15 (39
Atrial fibrillation 5 (13
Coronary artery disease 14 (37
BMI, kg/m2 27.8 
Systolic blood pressure, mm Hg 138 
Diastolic blood pressure, mm Hg 82 
Blood glucose, mmol/l 6 
Insulin, U/ml 8.05 
HOMA-R 2.15 
Total cholesterol, mmol/l 5.64 
HDL cholesterol, mmol/l 1.26 
Triglycerides, mmol/l 1.94 
Active therapy
Aspirin 28 (74
Warfarin 3 (8)
Beta-blocker 8 (21
Calcium channel blocker 6 (16
Statin 22 (58
ACE inhibitor 14 (37
Diuretic agent 8 (21
Angiotensin-2 antagonist 12 (32
Data are presented as mean  SD or n (%). *p  0.05 comp
group. The Kruskal-Wallis test was used to compare data fo
ACE  angiotensin-converting enzyme; BMI  body
ischemic attack.as applied to all specimens. The percentage of the total srea with positive color for each section was recorded.
nalysis of immunohistochemistry was performed with a
ersonal computer-based quantitative 24-bit color image
nalysis system (IM500, Leica Microsystem).
iochemical assays. Plaques were lysed and centrifuged for
0 min at 10,000 g at 4°C. After centrifugation, 20 g of
ach sample were loaded, electrophoresed in polyacrylamide
el, and electroblotted onto a nitrocellulose membrane.
ach determination was repeated at least three times.
biquitin, IkB-beta, MMP-9, and nitrotyrosine levels were
uantified in plaques using a specific ELISA kit (Santa
ruz; R&D Systems, Minneapolis, Minnesota; Imgenex,
an Diego, California). Nuclear extracts from plaque spec-
mens were obtained as described by Ohlsson et al. (17). We
sed a specific antibody that selectively recognizes the
ctivated form of the NFkB subunit p65. In addition, we
nalyzed the expression of the activated p50 subunit by
pecific Trans-AMNF-kB p50 transcription factor assay kit
Active Motif, Rixensart, Belgium). For the quantitative
easurement of the proteasome 20S activity, a specific
Symptomatic
Patients
Placebo Group
(n  20)
Rosiglitazone Group
(n  20)
72  3 71  2
11 (55) 12 (60)
9 (45) 8 (40)
8 (40) 9 (45)
3 (15) 4 (20)
9 (45) 8 (40)
7 (35) 8 (40)
5 (25) 4 (20)
9 (45) 8 (40)
6 (30) 7 (35)
7 (35) 6 (30)
27.9  3 28.1  3
139  11 140  12
80  6 82  4
6.07  1.4 6.06  1.3
8.06  2.4 8.08  2.7
2.17  1.3 2.18  1.3
5.63  0.09 5.67  0.10
1.22  0.08 1.21  0.09
1.95  0.31 1.97  0.34
19 (95) 18 (90)
2 (10) 1 (5)
5 (25) 6 (30)
3 (15) 2 (10)
19 (95) 18 (90)
11 (55) 10 (50)
4 (20) 5 (25)
9 (45) 8 (40)
ith placebo group. †p  0.05 compared with rosiglitazone
ycerides and insulin.
ndex; HDL  high-density lipoprotein; TIA  transientmatic
ts
roup
8)
2
)
)
)
)
)
)
)*†
)
2
12
5
0.9
2.2
0.9
0.09
0.10
0.33
)
)
)
)
)
)
)
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r triglodium dodecyl sulfate activation kit (Boston Biochem,
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June 20, 2006:2444–55 Ubiquitin-Proteasome Activity in Symptomatic Plaqueambridge, Massachusetts) was used. Nitrotyrosine was
ssayed into the plaque tissue with a kits supplied by Hycult
iotech (Uden, the Netherlands).
acrophages extraction from atherosclerotic plaques.
acrophages were selectively extracted from plaques as
igure 1. Representative example of plaques studied. This section is
epresentative of the plaque region analyzed. The section was stained
ith hematoxylin-eosin. Plaque section at low magnification. (A) A
arotid plaque from a patient affected by ipsilateral major stroke who
nderwent carotid endarterectomy within two months of symptom
nset. Fibrous cap plaque rupture with intraluminal thrombus is evident
magnification 2). (B) Carotid plaque from an asymptomatic patient,
haracterized by a large lipid core and a thin fibrous cap, without the
resence of acute thrombus within the lumen (magnification 2). (C)
icrograph showing immunohistochemical staining of carotid plaque
rom patient affected by ipsilateral major stroke. Fibrous cap adjacent to
upture site containing numerous macrophage-foam cells positive to
D68 antibody (brown chromogen) (magnification 100).escribed by de Vries et al. (18). Biochemical assay on cell lomogenates for ubiquitin and proteasome 20S determina-
ions were performed as illustrated earlier.
easurement of O2
. Production of O2
 was measured
s the superoxide dismutase-inhibitable reduction of cyto-
hrome c as previously described (19).
solation and culture of blood monocytes. Peripheral
lood monocytes from 20 symptomatic and 20 asymptom-
tic patients were purified and cultured as described by
ipollone et al. (20). In brief: human monocytes were
solated from buffy coat preparations purchased from the
ational Blood Transfusion Service or from whole blood
aken from laboratory donors. Mononuclear cells were first
solated by Ficoll-Hypaque sedimentation and then further
urified by Percoll density fractionation. Monocytes were
dentified by flow cytometry analysis according to their
haracteristic forward and side scatter on a Becton Dickin-
on FACScan flow cytometer. Purity was further checked
y expression of CD14 using monoclonal antibodies
Monoclonal Mouse Anti-Human CD14, Clone TU¨K4,
ako). The purity of monocytes ranged between 80% and
8%. Monocytes from symptomatic patients (24 106/4 ml
f DME) were cultured in the presence or absence of
osiglitazone (7.0 M for 48 h) and in the presence or
bsence of MG132 (Calbiochem, 10 mmol/l stock solutions
n dimethyl sulfoxide), a specific proteasome inhibitor (10
M for 5 h). At the end of the incubation, adherent
onocytes were scraped, collected, and lysed; and ubiquitin
Monoclonal anti-Ubiquitin, Clone 6C1, Sigma, ELISA),
roteasome 20S, NFk-B (Anti-NfkBp65, Anti-NfkBp50.
anta Cruz), IkB-beta (Anti-IKKb, Sigma), and O2
 pro-
uction were evaluated.
irius red staining for collagen content. Sections were
tained as described by Cipollone et al. (20). After dehy-
ration, the sections were observed under polarized light
fter being placed on coverslips. The sections were photo-
raphed with identical exposure settings for each section.
tatistical analysis. Data are presented as mean  SD.
ontinuous variables were compared among the groups of
atients with one-way analysis of variance for normally
istributed data and the Kruskal-Wallis test for non-
ormally distributed data. The Kolmogorov-Smirnov test
as used to assess whether continuous variables were nor-
ally distributed or not. We compared data using a
ruskal-Wallis test for triglycerides and insulin. When
ifferences were found among the groups, Bonferroni cor-
ection was used to make pairwise comparisons. The Bon-
erroni correction was used in the comparison of ubiquitin,
roteasome, p50, p65, IkB-beta, MMP-9, and O2
 pro-
uction values. A p value 0.05 was considered statistically
ignificant. All calculations were performed using the com-
uter program SPSS 12 (SPPS Inc., Chicago, Illinois).
ESULTS
tudy population. Demographic data for the study popu-
ation are presented in Table 1. Percentage of carotid
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Ubiquitin-Proteasome Activity in Symptomatic Plaque June 20, 2006:2444–55iameter reduction, risk factors, and concomitant therapy-
id not differ among the groups (Table 1). In symptomatic
atients, mean plasma glucose between week 0 and 16
ecreased similarly with placebo (0.18  0.06 mmol/l,
 0.25) and rosiglitazone (0.19  0.06 mmol/l, p 
.35). Insulin resistance index decreased in the rosiglitazone
roup but remained unchanged in the placebo group (p 
.01) (Table 2). No patient in either group developed any
linical events during the study.
laque composition. Plaque ulceration was significantly
ore common in the symptomatic plaques (22 of 40 [55%]
s. 7 of 38 [18%]; p 0.05). In contrast, no differences were
bserved with regard to intraplaque hemorrhage. Compared
ith asymptomatic patients, symptomatic patients all had
ignificantly greater portion of plaque area occupied by
acrophages (p  0.01) and T-lymphocytes (p  0.01), as
ell as greater expression of HLA-DR antigen (p  0.01)
nd smaller content of vascular smooth muscle cells
VSMCs) (p 0.01) (Table 2). Compared with the placebo
roup, the rosiglitazone group presented a significantly
maller portion of plaque area occupied by macrophages
p  0.01) and T-lymphocytes (p  0.01), as well as lower
xpression of HLA-DR and higher content of VSMC
p  0.01) (Table 3).
The MMP-9 levels were more abundant in symptomatic
ompared with asymptomatic lesions (p  0.001); in symp-
Table 2. Characteristics of Plaques Examined
Variables
Asymp
Pat
Contro
(n 
Stenosis severity, % 76.4
Macrophage-rich areas, % 6
T-cells per mm2 section area, number 16
Percentage of VSMC-rich areas 19
HLA-DR–rich areas, % 10
Data are presented as mean  SD or n (%). *p  0.05 comp
group.
VSMC  vascular smooth muscle cells.
able 3. Metabolic Parameters of Symptomatic Patients After
osiglitazone and Placebo Treatments
Variables
Symptomatic Patients
Placebo
Group
(n  20)
Rosiglitazone
Group
(n  20)
MI (kg/m2) 28.6  7 28.8  5
ystolic blood pressure (mm Hg) 126  13 126  15
iastolic blood pressure (mm Hg) 82  6 80  4
lood glucose (mmol/l) 6.1  1.7 6.2  1.9
nsulin (U/ml) 10.6  2.7 10.4  2.9
OMA-R 2.15  1.5 2.01  1.0
hanges in HOMA-R 0.1  0.02† 0.6  0.03
otal cholesterol (mmol/l) 5.63  0.14 5.62  0.18
DL cholesterol (mmol/l) 1.24  0.10 1.25  0.13
riglycerides (mmol/l) 1.81  0.39 1.86  0.56m
ata are presented as mean  SD. †p  0.05 compared with rosiglitazone group.
Abbreviations as in Table 1.omatic patients, MMP-9 levels were more abundant in
esions from placebo compared with the rosiglitazone group
p  0.001). Lower content of interstitial collagen was
ound in plaques of all symptomatic compared with asymp-
omatic patients. Content of interstitial collagen of plaques
rom rosiglitazone-treated patients was higher compared
ith that from placebo-treated patients (p  0.01) (Fig. 2).
biquitin-proteasome activity. Immunohistochemistry
evealed higher staining of ubiquitin and proteasome 20S in
nflammatory cells from symptomatic as compared with
symptomatic patients (p  0.01), with the highest staining
etected in patients randomized to placebo. A similar
attern of response was seen for ubiquitin plaque levels (p
.001) and proteasome 20S plaque activity (p  0.001)
Fig. 3).
BIQUITIN AND PROTEASOME 20S IN MACROPHAGES EX-
RACTED FROM PLAQUES. In order to identify whether the
igher ubiquitin-proteasome levels observed in symptomatic
laques were produced by macrophages, we repeated quan-
itative analyses on macrophages selectively extracted from
even plaques randomly selected from each of the three
roups. The small sample size used was not sufficient to
each an adequate statistical power for the comparisons
mong groups, so we can describe only the tendency of
entral measures for the three groups. However, we ob-
erved that the placebo symptomatic group had the highest
f both ubiquitin levels (468.7 89 ng/mg) and proteasome
0S activity (79.8  25 pmol/mg), the asymptomatic group
ad the lowest (ubiquitin 218  66 ng/mg; proteasome 20S
6.7  8 pmol/mg), and the rosiglitazone symptomatic
roup had intermediate levels (ubiquitin 322  79 ng/mg;
roteasome 20S 46.8  10 pmol/mg).
olocalization of proteasome 20S and ubiquitin with
acrophages in symptomatic plaques. Serial sections of
ymptomatic plaques were incubated with the primary
ntibodies anti-ubiquitin, anti-proteasome 20S, and anti-
D68. The expression of both ubiquitin and proteasome
0S were associated with CD68 macrophages in plaque
ections (Fig. 4). Thus, these analyses confirmed the con-
omitant presence of ubiquitin and proteasome 20S in
tic Symptomatic
Patients
up Placebo Group
(n  20)
Rosiglitazone Group
(n  20)
75.9  5.5 76.7  4.9
† 25  7 15  5*
† 73  16 40  15*
† 10  3 14  3*
† 29  4 17  5*
ith placebo group. †p  0.05 compared with rosiglitazonetoma
ients
l Gro
38)
 5.1
 3*
 8*
 7*
 2*
ared wacrophages of symptomatic plaque.
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June 20, 2006:2444–55 Ubiquitin-Proteasome Activity in Symptomatic PlaqueFkB activity. Nuclear factor kappa B activation, as re-
ected by the selective analysis of activated form of both p50
nd p65, was significantly higher in both placebo (p 0.01)
nd rosiglitazone (p 0.01) inflammatory cells as compared
ith macrophages from asymptomatic patients. In plaques
rom symptomatic patients, both p50 (p 0.01) and p65 (p
0.001) were significantly higher in placebo-treated than
n rosiglitazone-treated patients. Immunohistochemistry
nd quantitative analyses revealed lower staining and levels
igure 2. (A) Immunochemistry for matrix metalloproteinase (MMP)-9
symptomatic, placebo-treated, and rosiglitazone-treated symptomatic p
symptomatic, placebo-treated and rosiglitazone-treated symptomatic plaqu
or collagen content in asymptomatic, placebo-treated, and rosiglitazone-tr
pan from the 25th to 75th percentiles, and the error bars extend from the
ompared with rosiglitazone group.or IkB-beta in inflammatory cells from symptomatic as sompared with asymptomatic patients (placebo, p  0.01;
osiglitazone, p 0.001); moreover, both staining and levels
f IkB-beta were higher in rosiglitazone than in placebo
ymptomatic plaques (Fig. 5).
uantification of oxidative stress. Higher nitrotyrosine
evels were found in symptomatic plaques as compared with
symptomatic plaques (symptomatic placebo 3.5  0.42
mol/pg; symptomatic rosiglitazone 2.2  0.21 nmol/pg;
symptomatic group 1.1  0.29 nmol/pg, p  0.001). A
sirius red staining (630; box, 400) for collagen content (100) in
s. Similar regions of plaque are shown. These results are typical of
) Enzyme-linked immunosorbent assay for MMP-9 and sirius red staining
symptomatic plaques. (The central line represents the median, the boxes
to 90th percentiles.) *p  0.05 compared with placebo group. †p  0.05and
laque
es. (B
eatedimilar pattern was found for O2
 production (symptomatic
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roup 3.57  1.1 pmol/l; asymptomatic group 2.14  0.88
mol/l, p  0.01). In symptomatic patients, nitrotyrosine
evels and O2
 production were significantly higher in
laques from placebo-treated compared with rosiglitazone-
reated patients (nitrotyrosine: 3.5  0.42 nmol/pg vs.
.2  0.21 nmol/pg, p  0.01; O2
: 6.26  1.4 pmol/l vs.
.57  1.1, p  0.01).
n vitro study. Higher levels of ubiquitin, p50, p65, and
2
 production, as well as higher proteasome 20S and
ower IkB-beta levels, were evidenced in peripheral blood
igure 3. (A) Proteasome 20S (1,000) and ubiquitin (630) by immu
ymptomatic plaques. Similar regions of the plaque are shown (boxe
osiglitazone-treated symptomatic plaques. (B) Levels of proteasome 20S b
ssay kit *p  0.05 compared with placebo group. †p  0.05 compared wonocytes from 20 symptomatic patients compared with Monocytes from asymptomatic patients (p  0.01). Levels
f ubiquitin, p50, p65, and O2
 production, as well as pro-
easome 20S activity, were significantly lower in monocytes
rom symptomatic patients incubated with rosiglitazone
han in monocytes from symptomatic patients incubated
ithout rosiglitazone (p  0.01). The IkB-beta levels were
ignificantly higher in the symptomatic group monocytes
ncubated with rosiglitazone than in symptomatic group
onocytes incubated without rosiglitazone (p  0.01) (Fig.
). Levels of p50 and p65 levels were significantly lower in
onocytes from symptomatic patients incubated with
tochemistry in asymptomatic, placebo-treated, and rosiglitazone-treated
00). These results are typical of asymptomatic, placebo-treated, and
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siglitazone group.nohis
s, 2
y specG132 than in symptomatic patients’ monocytes incubated
w
n
n
1
s
i
M
i
d
4
D
T
t
s
u
a
s
l
l
r
i
M
a
u
u
h
H
t
u
h
p
H
s
u
a
C
t
t
T
a
i
m
c
s
a
H
f
s
t
p
N
b
m
s
p
p
i
w
i
p
O
p
p
A
i
i
s
b
a
o
c
a
b
d
p
m
t
p
w
i
R
F
f symp
2451JACC Vol. 47, No. 12, 2006 Marfella et al.
June 20, 2006:2444–55 Ubiquitin-Proteasome Activity in Symptomatic Plaqueithout MG132 (p50: 15.9  1.4 ng/mg vs. 21  1.7
g/mg, p  0.01; p65: 22  2.9 ng/mg vs. 31.5  1.6
g/mg, p  0.01), whereas IkB-beta (33.6  7.9 ng/mg vs.
8  2.2 ng/mg, p  0.01) was significantly higher in the
ymptomatic group monocytes incubated with MG132 than
n symptomatic group monocytes incubated without
G132. Although ubiquitin levels were higher in monocytes
ncubated with MG132, there were no statistically significant
ifferences among the groups (429.9  27.8 ng/mg vs. 414 
9.8 ng/mg, p  0.2).
ISCUSSION
his study shows that ubiquitin-proteasome system overac-
ivity is associated with the inflammatory process in athero-
clerotic plaques of symptomatic patients. In particular, the
biquitin-proteasome activity was greater in symptomatic
therosclerotic lesions as compared with asymptomatic le-
ions and was associated with higher NFkB and MMP-9
evels along with a lesser interstitial collagen content and a
esser VSMC content. These alterations might increase the
isk of future acute ischemic events precipitated by
nflammatory-dependent rupture of atherosclerotic plaques.
oreover, we provide evidence that the PPAR-gamma
gonist rosiglitazone may prevent plaque progression to an
nstable phenotype in symptomatic patients by reducing
biquitin-proteasome activity.
A previous postmortem study (11) has reported en-
anced ubiquitin expression in unstable coronary plaques.
owever, the study did not provide any evidence about
he specific pathway transducing environmental stimuli in
biquitin-proteasome overexpression in subgroups of
igh-risk plaques such as those found in symptomatic
atients. In our study, macrophages, T-lymphocytes, and
DLA-DR inflammatory cells were more abundant in
ymptomatic plaques and represented the major source of
biquitin-proteasome activity, suggesting the presence of
n active inflammatory reaction in symptomatic plaques.
oncomitantly higher expression of ubiquitin and pro-
easome was found in human plaque macrophages ob-
ained from the carotid lesions of patients with recent
IA or stroke compared with specimens obtained from
igure 4. Consecutive immunostaining (200) using serial sections of sym
or proteasome 20S and ubiquitin. These results are typical of 12 placebosymptomatic patients. In agreement with the difference sn ubiquitin-proteasome staining pattern, the histologic
ilieu of the lesions appears different with regard to
ellularity, but not in the degree of vessel stenosis,
uggesting that symptomatic and asymptomatic lesions
re different only with regard to inflammatory burden.
ence, the differences in plaque behavior likely stem
rom differences in the presence of stimuli (i.e. oxidative
tress, as evidenced by high O2
 production and nitro-
yrosine levels) for selective expression of ubiquitin-
roteasome, capable of disrupting plaque stability via
FkB induction. Nuclear factor kappa B is normally
ound to IkB in the cytosol; this binding prevents its
ovement into the nucleus (21). Various cellular stimuli,
uch as oxidative stress, induce ubiquitination of phos-
horylated IkBs and subsequent degradation by the
roteasome (22). Degradation of IkBs results in unmask-
ng of the nuclear localization signal of NFkB dimers,
hich subsequently translocates to the nucleus, where it
nduces the transcription of proinflammatory cytokines that
lay a central role in plaque instability progression (23,24).
ur findings also suggest that oxidative stress may induce
hosphorylation and degradation of IkBs via the ubiquitin–
roteasome overactivity, thus enhancing NFkB activation.
ccording to the response-to-injury theory, atherosclerosis
s initiated as an inflammatory-proliferative response to an
njurious stimulus, constituted by cardiovascular risk factors
uch as hypercholesterolemia, hypertension, smoking, dia-
etes, and age (23). This injurious stimulus seems to be
ggravation of endogenous oxidative stress, leading to the
xidative modification of lipids, proteins, and deoxyribonu-
leic acid, and thereby to structural and functional alter-
tions within the vascular wall (25). Reduction in the
ioavailability of nitric oxide (NO) due to increased pro-
uction of reactive oxygen species is another important
athophysiologic element in atherogenesis (26). Under nor-
al conditions, NO is constitutively produced by endo-
helial cells, antagonizing pro-atherosclerotic processes in
art by suppressing the transcriptional activity of NFkB,
hich has been identified as a pivotal mediator in the
nflammatory-proliferative process of atherogenesis (27).
eduction in NO bioavailability as well as alteration of cell
atic plaques demonstrated that cells positive for CD68 were also positive
tomatic plaques.ptomignaling pathways due to an increase in oxidative stress,
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eports evidenced the involvement of the ubiquitin–
roteasome system in NFkB activation, particularly under
onditions of aggravated oxidative stress. Oxidative stress is
he common factor underlying hypercholesterolemia, hyper-
ension, smoking, diabetes, and age and cardiovascular
isease, and may explain the presence of inflammation in all
igure 5. (A) Levels of activated nuclear factor kappa B (specific Tra
symptomatic, placebo-treated, and rosiglitazone-treated symptomatic plaq
kB-beta (800). Similar regions of the plaque are shown. These res
ymptomatic plaques. *p  0.05 compared with placebo group. †p  0.05hese conditions (29). Although it is well recognized that pnflammation is one manifestation of oxidative stress, and
he pathways that generate the mediators of inflammation,
uch as interleukins, are all induced by oxidative stress (30),
he mechanism by which oxidative stress may be involved in
nflammatory process of symptomatic plaques is not fully
larified. In this context, our data suggest a novel mecha-
ism by which oxidative stress, increasing ubiquitin-
p50 and p65 subunit assay kit) and inhibitory kappa B (IkB)-beta
B) immunohistochemistry for activated p65 (630) and p50 (630) and
are typical of asymptomatic, placebo-treated, and rosiglitazone-treated
pared with rosiglitazone group.ns-AM
ues; (
ults
comroteasome activity, may mediate inflammatory activity in
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hown that oxidative stress can stimulate the ubiquitin
ystem in macrophages by inducing the expression of
omponents of its enzymatic machinery such as ubiquitin-
inding proteins (31). Accordingly, in cultured monocytes
rom symptomatic patients we evidenced that O2
 produc-
ion as well as ubiquitin-proteasome activity and NFkB
evels were significantly higher when compared to asymp-
igure 6. Ubiquitin, proteasome 20S, activated NFkB, IkB-beta, and O2

onocytes were cultured in presence or absence (48 h) of rosiglitazone (7.0
ith rosiglitazone-treated symptomatic monocytes. Abbreviations as in Fiomatic patients. Thus, we can speculate that increased sbiquitin-proteasome activity in plaque macrophage as a
onsequence of oxidative stress overexpression may enhance
he synthesis of NFkB in the same cell, possibly represent-
ng a crucial step in the pathophysiology of plaque instabil-
ty. Because of the study design, we cannot exclude whether
he ubiquitin-proteasome pathway exerts also a protective
ompensatory response (32), or whether it is merely a
orrelative marker for the presence of inflammatory cells in
ction in symptomatic and asymptomatic monocytes. Purified symptomatic
. *p  0.05 compared with symptomatic monocytes. †p  0.05 compared
.produ
M)ymptomatic lesions. However, the concomitant presence of
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Ubiquitin-Proteasome Activity in Symptomatic Plaque June 20, 2006:2444–55biquitin and proteasome 20S in macrophages of symptom-
tic patients, as well as the reduction of NFkB levels in
onocytes from symptomatic patients treated with protea-
ome inhibitor suggests that the ubiquitin-proteasome
athway may have a pro-inflammatory effect in symptom-
tic lesions. Moreover, higher expression of ubiquitin-
roteasome and MMP-9 in symptomatic plaques, one of
he most important enzymes in the process of atheroscle-
otic plaque rupture (33), along with a lesser interstitial
ollagen content suggests an involvement of the ubiquitin
roteasome system in instability of symptomatic lesion by
ncreasing plaque erosion.
The present findings also show an inhibitory effect of
osiglitazone on ubiquitin-proteasome activity in symp-
omatic lesions. Indeed, symptomatic patients treated
ith rosiglitazone had the lowest level of ubiquitin and
roteasome 20S activity, plaque inflammatory cells, cy-
okines, oxidative stress, and MMP-9 associated with the
ighest content of plaque interstitial collagen and VSMC
ontent. Thus, patients assigned to rosiglitazone had less
laque progression to rupture compared with patients
ssigned to placebo. In particular, the reduced ubiquitin-
roteasome activity seen in symptomatic plaques of the
osiglitazone group suggests decreased IkBs degradation
nd hence NFkB activation. All this may have clinical
mplications, because in a large series of carotid endar-
erectomy specimens, it has been shown that plaque
nflammation is one of the major determinants of isch-
mic events in patients affected by carotid atherosclerotic
isease (1). Sufficient data in humans suggest that
PAR-gamma agonists reduce common carotid arterial
ntima-media thickness progression as well as circulating
arkers of inflammation as early as three months after
he administration in both nondiabetic and diabetic
atients (12,15). Moreover, there are accumulating data
o suggest that PPAR-gamma agonists exert anti-
nflammatory and antioxidant effects, including decreases
f cytokines and MMPs in monocytes, macrophages,
-lymphocytes, and VSMC (34,35). Although PPAR-
amma agonists may inhibit proteasome activity in hu-
an cancer (36), until now there was no evidence that
his effect was reproducible in human atherosclerotic
laques. The hypothesis that plaque ubiquitin-
roteasome activity is reduced by PPAR-gamma agonists
s also supported by our in vitro experiment that evi-
enced a reduction of ubiquitin-proteasome activity,
FkB levels, and O2
 production associated with a
ignificant increment of IkB-beta in monocytes from
ymptomatic patients treated with rosiglitazone. The
echanism of repression of the proteasome by rosiglita-
one remains a mystery and requires further studies. On
he other hand, the reduction in O2
 production by
onocytes after rosiglitazone treatment may allow a
ower polyubiquitination, as evidenced by reduction of
biquitin levels. We therefore speculated that proteasome
eduction by rosiglitazone may be induced by inhibition lf oxidative stress and polyubiquitination. Rosiglitazone
reatment also produced a significant reduction in insulin
esistance, as indicated by reduced insulin resistance
ndex levels. As insulin resistance is associated with
ncreased cardiovascular and cerebrovascular risk (37),
mproved insulin sensitivity may be one mechanism by
hich rosiglitazone retards atherogenesis progression.
n the other hand, oxidative stress has been shown to
nduce insulin resistance through NFkB activation (38):
n this perspective, rosiglitazone, by reducing oxidative
tress and ubiquitin-proteasome activity, may enhance
oth insulin sensitivity and symptomatic plaque stability.
e also do not exclude the possibility that rosiglitazone
nhibits NFkB activation through additional mechanisms
ndependent of PPAR-gamma. Indeed, a PPAR-
amma–independent pathway may be operative in neu-
onal cells via inhibition of inducible nitric oxide synthase
39). Furthermore, PPAR-gamma agonists inhibit the
uclear translocation and subsequent deoxyribonucleic
cid binding of NFkB via an IkBs-dependent pathway by
nhibiting the immune response-induced degradation of
kBs (40). This provides evidence that a component of
he anti-inflammatory effect is mediated by the action of
PAR-gamma agonists on the systemic immune system.
lthough further investigation will be required to eluci-
ate the upstream mechanisms by which PPAR-gamma
nhibits the degradation of IkBs, inhibition of cytokine
ene expression suggests that activation of PPAR-gamma
ay alter functional elements common to both these
athways.
This study demonstrates enhanced ubiquitin-
roteasome activity in symptomatic atherosclerotic le-
ions and provides evidence that the activation of this
ystem by macrophages is associated with an NFkB-
ependent increase in inflammation, potentially promot-
ng plaque rupture. Moreover, the present study addresses
he missing link between thiazolidinedione therapy and
FkB activity, which leads in turn to plaque stabiliza-
ion, by demonstrating the inhibition of the ubiquitin-
roteasome activity in human atherosclerotic lesions of
ymptomatic patients after rosiglitazone therapy and
roviding evidence that down-regulation of ubiquitin-
roteasome activity is associated with plaque stabiliza-
ion, possibly by suppression of NFkB-induced inflam-
ation. These findings are potentially important from a
undamental standpoint because they indicate a crucial
ole for the inhibition of ubiquitin-proteasome activity in
he stabilization of atherosclerotic lesions observed with
hiazolidinediones. From a practical standpoint, these
ndings provide further support for the possibility that
hiazolidinediones might provide a novel form of therapy
or plaque stabilization in patients with atherosclerotic
isease. However, these results require further confirma-
ion from studies evaluating the effects of thiazo-
idinediones on a higher number of patients.
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